Literature DB >> 25552563

Long-term results of transapical versus transfemoral TAVI in a real world population of 1000 patients with severe symptomatic aortic stenosis.

Gerhard Schymik1, Alexander Würth2, Peter Bramlage2, Tanja Herbinger2, Martin Heimeshoff2, Lothar Pilz2, Jan S Schymik2, Rainer Wondraschek2, Tim Süselbeck2, Jan Gerhardus2, Armin Luik2, Bernd-Dieter Gonska2, Herbert Posival2, Claus Schmitt2, Holger Schröfel2.   

Abstract

BACKGROUND: Transapical transcatheter aortic valve implantation is generally perceived to be associated with increased morbidity compared with transfemoral transcatheter aortic valve implantation. We aimed to compare access-related complications and survival using propensity score matching. METHODS AND
RESULTS: Prospective, single-center registry of 1000 consecutive patients undergoing transapical and transfemoral transcatheter aortic valve implantation between May 2008 and April 2012. Transapical was performed in 413 patients and transfemoral in 587 patients. Patients with transapical access were less often women and less had pulmonary hypertension. Further they had more peripheral arterial disease, coronary artery disease, carotid stenosis, and recurrent surgery and a higher logistic EuroSCORE I (24.3% ± 16.2% for transapical versus 22.2% ± 16.2% for transfemoral; P < 0.01). After building 2 propensity score-matched groups of 354 patients each with either access route (total 708 patients), baseline characteristics were comparable. In this analysis, there was no significant difference in 30 day mortality (5.9% transapical versus 8.5% transfemoral; P = 0.19), the rate of myocardial infarction (2.5% transapical versus 2.0% transfemoral; P = 0.61), stroke (2.0% transapical versus 2.3% transfemoral; P = 0.79), bleeding complications, pacemaker implantation rates, or moderate aortic insufficiency. Stage 1 renal complications were more common in transapical patients (odds ratio, 2.81; 95% confidence interval, 1.93-4.09), whereas major vascular complications were less common (odds ratio, 0.14; 95% confidence interval, 0.06-0.29). Survival probability over the long term was not statistically different (hazard ratio, 0.89; 95% confidence interval, 0.72-1.10; log-rank Test, P = 0.27).
CONCLUSIONS: The data demonstrate that in an experienced multidisciplinary heart team, either access route can be performed with comparable results.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  aortic valve replacement; mortality; transcatheter

Mesh:

Year:  2014        PMID: 25552563     DOI: 10.1161/CIRCINTERVENTIONS.113.000761

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  23 in total

1.  Transcaval Access and Closure for Transcatheter Aortic Valve Replacement: A Prospective Investigation.

Authors:  Adam B Greenbaum; Vasilis C Babaliaros; Marcus Y Chen; Annette M Stine; Toby Rogers; William W O'Neill; Gaetano Paone; Vinod H Thourani; Kamran I Muhammad; Robert A Leonardi; Stephen Ramee; James F Troendle; Robert J Lederman
Journal:  J Am Coll Cardiol       Date:  2016-10-29       Impact factor: 24.094

Review 2.  Current rare indications and future directions for implantable loop recorders.

Authors:  Simon Wechselberger; Christopher Piorkowski; Matthias Pohl
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-12

3.  In-hospital outcomes comparison of transfemoral vs transapical transcatheter aortic valve replacement in propensity-matched cohorts with severe aortic stenosis.

Authors:  Rajkumar Doshi; Priyank Shah; Perwaiz M Meraj
Journal:  Clin Cardiol       Date:  2018-03-24       Impact factor: 2.882

4.  Understanding Neurologic Complications Following TAVR.

Authors:  Ghare Mohammed Imran; Lansky Alexandra
Journal:  Interv Cardiol       Date:  2018-01

5.  Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Therapy Registry.

Authors:  Alexander C Fanaroff; Pratik Manandhar; David R Holmes; David J Cohen; J Kevin Harrison; G Chad Hughes; Vinod H Thourani; Michael J Mack; Matthew W Sherwood; W Schuyler Jones; Sreekanth Vemulapalli
Journal:  Circ Cardiovasc Interv       Date:  2017-10       Impact factor: 6.546

Review 6.  Long term outcomes of transcatheter aortic valve implantation (TAVI): a systematic review of 5-year survival and beyond.

Authors:  Adam Chakos; Ashley Wilson-Smith; Sameer Arora; Tom C Nguyen; Abhijeet Dhoble; Giuseppe Tarantini; Matthias Thielmann; John P Vavalle; Daniel Wendt; Tristan D Yan; David H Tian
Journal:  Ann Cardiothorac Surg       Date:  2017-09

7.  Fully percutaneous transthoracic left atrial entry and closure as a potential access route for transcatheter mitral valve interventions.

Authors:  Toby Rogers; Kanishka Ratnayaka; William H Schenke; Merdim Sonmez; Ozgur Kocaturk; Jonathan R Mazal; Marcus Y Chen; Moshe Y Flugelman; James F Troendle; Anthony Z Faranesh; Robert J Lederman
Journal:  Circ Cardiovasc Interv       Date:  2015-06       Impact factor: 6.546

Review 8.  Matching patients with the ever-expanding range of TAVI devices.

Authors:  Brandon M Jones; Amar Krishnaswamy; E Murat Tuzcu; Stephanie Mick; Wael A Jaber; Lars G Svensson; Samir R Kapadia
Journal:  Nat Rev Cardiol       Date:  2017-07-06       Impact factor: 32.419

Review 9.  [Transcatheter aortic valve implantation (TAVI): Current perspectives].

Authors:  Luise Gaede; Helge Möllmann
Journal:  Herz       Date:  2015-08       Impact factor: 1.443

10.  Long-term outcomes and prosthesis performance after transcatheter aortic valve replacement: results of self-expandable and balloon-expandable transcatheter heart valves.

Authors:  Giuseppe Tarantini; Paola A M Purita; Augusto D'Onofrio; Chiara Fraccaro; Anna Chiara Frigo; Gianpiero D'Amico; Luca Nai Fovino; Marta Martin; Francesco Cardaioli; Mostafa R A Badawy; Massimo Napodano; Gino Gerosa; Sabino Iliceto
Journal:  Ann Cardiothorac Surg       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.